JMS Co

JMS Co Equity Ratio

The Equity Ratio of JMS Co (7702.T) as of Nov 2, 2026 is 50.24 %. In the previous year, Equity Ratio was 50.15 % — a change of 0.18% (higher).

Equity Ratio

50.24 %

YoY

0.18%

Last updated:

Equity Ratio of JMS Co is 2026 50.24 % . Equity Ratio of JMS Co was 2025 50.15 % . It decreases by 0.18% higher compared to the previous year.

The JMS Co Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
47.19 JPY
Jan 1, 2020
48.58 JPY
Jan 1, 2021
50.43 JPY
Jan 1, 2022
51.35 JPY
Jan 1, 2023
51.78 JPY
Jan 1, 2024
47.90 JPY
Jan 1, 2025
50.15 JPY
Jan 1, 2026
50.24 JPY
The JMS Co Equity Ratio history
YEAREquity RatioYoY
50.24 %+0.18%
50.15 %+4.70%
47.90 %-7.51%
51.78 %+0.84%
51.35 %+1.83%
50.43 %+3.82%
48.58 %+2.95%
47.19 %+1.07%
46.69 %-0.86%
47.09 %-0.32%
47.24 %-9.10%
51.97 %-9.39%
57.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JMS Co Stock analysis

What does JMS Co do? JMS Co., Ltd. generates revenue through the manufacture, sale, export, and import of medical devices and pharmaceuticals across its five geographical segments: Japan, Singapore, China, Philippines, and Germany. The company offers a range of products including infusion and nutrition products, dialysis products, surgery products, blood and cell products, and other related items. Key products such as infusion & transfusion sets, syringe pumps, surgical gowns, dialysis kits, peritoneal dialysate, microcatheters, and blood bags are sold to healthcare providers and institutions within these regions. The firm also provides maintenance services and other related services as part of its product portfolio. The company's primary customers are healthcare providers and institutions in Japan, Singapore, China, Philippines, and Germany, where it operates through its five geographical segments. These customers purchase medical equipment and drugs, including specific items like infusion & transfusion sets, dialysis kits, and surgical gowns. The firm's product lines are tailored to meet the needs of hospitals, clinics, and other medical facilities across its operational regions. JMS Co., Ltd. focuses on manufacturing and selling medical equipment and drugs, with a strong emphasis on products such as infusion & transfusion sets, syringe pumps, surgical gowns, and dialysis kits. The company's revenue streams are driven by the sale of these products and the provision of maintenance services. Its geographical segments ensure a diversified market presence, allowing it to serve various healthcare sectors in different countries. JMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JMS Co stock

Equity Ratio of JMS Co is 50.24 % in 2026.

Equity Ratio of JMS Co changed from 50.15 % to 50.24 %, representing a 0.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio JMS Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's JMS Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — JMS Co

All Key Metrics — JMS Co